3O8 Stock Chart & Stats
€16.10
€0.35(3.57%)
At close: 4:00 PM EDT
€16.10
€0.35(3.57%)
Day’s Range― - ―
52-Week Range€3.48 - €18.05
Previous CloseN/A
Volume0.00
Average Volume (3M)18.00
Market Cap
€1.27B
Enterprise Value€1.02B
Total Cash (Recent Filing)€131.95M
Total Debt (Recent Filing)€83.77M
Price to Earnings (P/E)9.9
Beta0.35
Next Earnings
Nov 11, 2026EPS Estimate
0.03Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.91
Shares Outstanding72,388,310
10 Day Avg. Volume8
30 Day Avg. Volume18
Financial Highlights & Ratios
PEG Ratio3.32
Price to Book (P/B)-9.00
Price to Sales (P/S)0.00
P/FCF Ratio-9.39
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€24.54Price Target Upside52.43% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)0.78
Revenue Forecast (FY)€109.68M
Bulls Say, Bears Say
Bulls Say
Yartemlia Commercial TractionYartemlia’s strong first full quarter, rapid sequential sales growth, and expansion across ordering accounts indicate meaningful physician adoption and commercial execution. Continued penetration of U.S. transplant centers could establish a durable revenue base and support broader investment in the company’s pipeline.
U.S. Reimbursement SupportA permanent product-specific J-code and substantial NTAP reimbursement improve hospitals’ ability to obtain payment for Yartemlia, reducing an important adoption barrier. Consistent commercial-payer prior-authorization approvals further support durable access and expansion in the U.S. transplant market.
Pipeline And Partnership DepthThe phase 2-ready MASP-2 program and additional early-stage assets give Omeros multiple opportunities beyond its current commercial launch. The Novo Nordisk partnership also supplies external validation and potential milestone funding, improving the strategic value and optionality of the development platform.
Bears Say
Negative Shareholder EquityPersistently negative shareholder equity weakens Omeros’s financial flexibility and makes the capital structure harder to underwrite. Even after debt reduction, the lack of a positive equity cushion can increase refinancing pressure and constrain the company’s ability to fund development and commercial expansion internally.
Ongoing Cash BurnThe return to sizable operating and free-cash-flow outflows indicates that reported profitability is not yet translating consistently into internally generated cash. Continued burn could require additional financing before the stated mid-2027 positive-cash-flow target, limiting flexibility across clinical and commercial priorities.
European Regulatory SetbackThe negative CHMP opinion delays or complicates Yartemlia’s European commercialization path and reduces the near-term geographic reach of the product. Although Omeros requested reexamination, the regulatory setback creates uncertainty around approval timing and the resources required to pursue that market.
Omeros News
3O8 FAQ
What was Omeros Corp’s price range in the past 12 months?
Omeros Corp lowest stock price was €3.48 and its highest was €18.05 in the past 12 months.
What is Omeros Corp’s market cap?
Omeros Corp’s market cap is €1.27B.
When is Omeros Corp’s upcoming earnings report date?
Omeros Corp’s upcoming earnings report date is Nov 11, 2026 which is in 27 days.
How were Omeros Corp’s earnings last quarter?
Omeros Corp released its earnings results on Aug 12, 2026. The company reported €0.134 earnings per share for the quarter, beating the consensus estimate of -€0.239 by €0.373.
Is Omeros Corp overvalued?
According to Wall Street analysts Omeros Corp’s price is currently Undervalued.
Does Omeros Corp pay dividends?
Omeros Corp does not currently pay dividends.
What is Omeros Corp’s EPS estimate?
Omeros Corp’s EPS estimate is 0.03.
How many shares outstanding does Omeros Corp have?
Omeros Corp has 72,388,310 shares outstanding.
What happened to Omeros Corp’s price movement after its last earnings report?
Omeros Corp reported an EPS of €0.134 in its last earnings report, beating expectations of -€0.239. Following the earnings report the stock price went up 26.891%.
Which hedge fund is a major shareholder of Omeros Corp?
Currently, no hedge funds are holding shares in DE:3O8
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Omeros Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€24.54 (52.43% Upside)
€24.54 (52.43% Upside)
Blogger Sentiment
Bullish
DE:3O8 Sentiment 93%
Sector Average 67%
Sector Average 67%
Insider Transactions
Sold Shares
Worth €1.3M over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Positive
20 days / 200 days
Momentum
350.59%
12-Months-Change
Fundamentals
Return on Equity
-109.40%
Trailing 12-Months
Asset Growth
43.01%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Omeros Corp
Omeros Corporation is a biopharmaceutical firm with commercialized products, actively engaged in the discovery, development, and market introduction of both small-molecule and protein-based therapies, including treatments for rare diseases. The company's therapeutic endeavors primarily focus on inflammatory conditions, illnesses mediated by the complement system, cancers linked to immune system dysregulation, and disorders characterized by addiction or compulsion. Its robust clinical pipeline features several promising candidates. Narsoplimab (also known as OMS721 or MASP-2), a leading asset, has successfully concluded pivotal trials for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (HSCT-TMA). This drug is also currently undergoing Phase III clinical evaluation for immunoglobulin A nephropathy (IgAN) and atypical hemolytic uremic syndrome (aHUS), in addition to a Phase II trial investigating its potential for treating COVID-19. Further expanding its clinical portfolio, Omeros is developing PPAR? (OMS405) in Phase II for opioid and nicotine dependence. PDE7 (OMS527) is progressing through Phase I studies for addiction, compulsive disorders, and movement disorders. Additionally, MASP-3 (OMS906) is currently in Phase I trials for paroxysmal nocturnal hemoglobinuria (PNH) and other conditions involving the alternative complement pathway. Beyond its clinical efforts, the company maintains a dynamic preclinical program. This includes small-molecule inhibitors targeting MASP-2, which are being explored for applications in aHUS, IgAN, HSCT-TMA, and age-related macular degeneration. Also in development is a next-generation, longer-acting antibody that targets MASP-2, alongside MASP-3 small-molecule inhibitors designed to address PNH and other alternative pathway disorders. Omeros's preclinical research further encompasses GPR174 inhibitors, as well as Chimeric Antigen Receptor (CAR) T-Cell and Adoptive T-Cell Therapies for various oncological indications. The company is also investigating G protein-coupled receptor targets for a broad spectrum of diseases, including immunological, immuno-oncological, metabolic, central nervous system (CNS), cardiovascular, musculoskeletal, and other conditions. Established in 1994, Omeros Corporation is headquartered in Seattle, Washington.
3O8 Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call highlights a successful commercial launch for Yartemlia with very strong quarter-over-quarter sales growth (190% gross, 188% net), positive operating cash flow, meaningful balance sheet improvements via share and note repurchases, reimbursement wins (J-code and NTAP), and progress across a diversified pipeline and strategic partnership with Novo Nordisk. Offsetting items include a negative CHMP opinion in Europe, accounting volatility from derivative mark-to-market adjustments and repurchase-related losses, expected near-term increases in operating expenses, limited patient-level visibility, and one-time reimbursement items that temper recurring income visibility. On balance, the operational and commercial positives—especially the rapid U.S. uptake, cash generation, and reduced leverage/dilution—outweigh the challenges, which are largely manageable or noncash/one-time in nature.View all DE:3O8 earnings summaries3O8 Stock 12 Month Forecast
Average Price Target
€24.54
▲(52.43% Upside)